Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2021

View Archived Issues

First preclinical data presented for chimeric fusion protein AT-03 in amyloidosis

The GABA aminotransferase inhibitor OV-329 shows anticonvulsant effects in two rat seizure models

ACE2-IgG4-Fc fusion protein neutralizes SARS-CoV-2, including several variants, at pM concentration

Targeting S100A7/RAGE signaling pathway inhibits breast tumorigenesis

Factor V/Va-targeting MAb GB-5 promotes thrombus formation in vivo for treating bleeding disorders

TAXIS Pharmaceuticals divulges bacterial efflux pump inhibitors

Sanofi patents IL-17A/IL-17RA interaction inhibitors

Pfizer synthesizes new JAK1 inhibitors

Eli Lilly and Company presents new NTRK1 inhibitors

Proof of concept for novel NASH approach

Janssen discloses DHODH inhibitors

Researchers discover novel genes tied to classical Hodgkin's lymphoma predisposition

ELU-001 shows efficacy and safety in preclinical models of FRalpha-overexpressing cancers

Development of novel mouse model of Dravet syndrome

iECURE and Penn to develop next-generation LNPs for liver gene editing applications

Sosei and Twist collaborate to discover therapeutic antibodies against GPCR targets

Design of novel SSTR2 agonists for acromegaly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...